Orforglipron and retatrutide from Eli Lilly exemplify the next generation of metabolic therapies: oral formulations that promise improved adherence, triple-hormone mechanisms that deliver superior weight loss and expanded therapeutic applications spanning from brain health to renal disease". For 2026, pharma executives must recognize that metabolic innovation extends far beyond replicating existing GLP-1 therapies, the report authors wrote
William Vasquez Founder & CEO, Vasquez Law Firm, PLLC William Vasquez is the founder and CEO of Vasquez Law Firm, PLLC, a results-driven firm specializing in immigration, criminal defense, personal injury, and workers' compensation
Abadilla, K
What happens after delivery: resuming tirzepatide Many women want to resume tirzepatide after pregnancy
A special solution is used to freeze the spot
The first step on any ladder, and a gentle re-entry after a break